利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.028 秒)

    METHOD FOR DIAGNOSING LIVER FIBROSIS
    1.
    发明申请
    METHOD FOR DIAGNOSING LIVER FIBROSIS 审中-公开
    用于诊断肝纤维化的方法

    公开(公告)号：US20070178443A1

    公开(公告)日：2007-08-02

    申请号：US11673072

    申请日：2007-02-09

    申请人： Ursula-Henrike Wienhues-Thelen ,  Paul Cales ,  Hendrik Huedig

    发明人： Ursula-Henrike Wienhues-Thelen ,  Paul Cales ,  Hendrik Huedig

    IPC分类号： C12Q1/00 ,  C12Q1/37

    CPC分类号： G01N33/6893 ,  G01N2333/745 ,  G01N2333/81 ,  G01N2333/8146 ,  G01N2800/085 ,  G01N2800/52

    摘要： The invention concerns a method for the detection of the presence and/or the severity of a liver disease in a patient comprising measuring in an isolated sample TIMP-1 (Tissue Inhibitor of Metalloproteinase I), A2M (a-2-macroglobulin), PLT (number of blood plateletes, PI (prothrombin index), optionally at least one additional parameter selected from the group consisting of urea and GGT (γ-glutamyltranspeptidase) and optionally measuring at least one additional biochemical or clinical parameter and diagnosing the presence and/or severity of a liver disease based on the presence or measured levels of these parameters. The method can be used for monitoring therapeutic treatment of liver fibrosis and staging of liver fibrosis.

    摘要翻译： 本发明涉及用于检测患者肝脏疾病存在和/或严重程度的方法，包括在分离的样品中测量TIMP-1（金属蛋白酶I的组织抑制剂），A2M（a-2-巨球蛋白），PLT （血小板数，PI（凝血酶原指数）），任选地至少一种选自脲和GGT（γ-谷氨酰转肽酶）的附加参数，并任选地测量至少一种额外的生物化学或临床参数，并诊断存在和/或 基于这些参数的存在或测量水平，肝脏疾病的严重程度，可用于监测肝纤维化的治疗和肝纤维化分期。

    METHOD FOR DIAGNOSING LIVER FIBROSIS
    2.
    发明申请
    METHOD FOR DIAGNOSING LIVER FIBROSIS 审中-公开
    用于诊断肝纤维化的方法

    公开(公告)号：US20070178442A1

    公开(公告)日：2007-08-02

    申请号：US11673058

    申请日：2007-02-09

    申请人： Ursula-Henrike Wienhues-Thelen ,  Paul Cales ,  Hendrik Huedig

    发明人： Ursula-Henrike Wienhues-Thelen ,  Paul Cales ,  Hendrik Huedig

    IPC分类号： C12Q1/00 ,  C12Q1/37

    CPC分类号： G01N33/6893 ,  G01N2333/745 ,  G01N2333/81 ,  G01N2333/8146 ,  G01N2800/085

    摘要： A method for the detection of the presence and/or the severity of a liver disease in a patient comprising measuring in an isolated sample TIMP-1 (tissue inhibitor of metalloproteinase I), ferritin, at least one additional parameter selected from the group consisting of A2M (alpha-2-macroglobulin) and PI (prothrombin index) and optionally measuring at least one additional biochemical or clinical parameter and diagnosing the presence and/or severity of a liver disease based on the presence or measured levels of these parameters. The method can be used for monitoring therapeutic treatment of liver fibrosis and staging of liver fibrosis.

    摘要翻译： 一种用于检测患者中肝脏疾病的存在和/或严重性的方法，其包括在分离的样品TIMP-1（金属蛋白酶I的组织抑制剂），铁蛋白中测量至少一种附加参数，所述附加参数选自： A2M（α-2-巨球蛋白）和PI（凝血酶原指数），并且任选地基于这些参数的存在或测量水平测量至少一种额外的生物化学或临床参数并诊断肝脏疾病的存在和/或严重性。 该方法可用于监测肝纤维化的治疗和肝纤维化分期。

    USE OF BIGLYCAN IN THE ASSESSMENT OF HEART FAILURE
    3.
    发明申请
    USE OF BIGLYCAN IN THE ASSESSMENT OF HEART FAILURE 审中-公开
    大智慧在评估心脏失败时的使用

    公开(公告)号：US20110165591A1

    公开(公告)日：2011-07-07

    申请号：US13048196

    申请日：2011-03-15

    申请人： Ursula-Henrike Wienhues-Thelen ,  Sara Arab ,  Dirk Block ,  Andrew Emili ,  Anthony Gramolini ,  Georg Hess ,  Hendrik Huedig ,  Peter Liu ,  David MacLennan

    发明人： Ursula-Henrike Wienhues-Thelen ,  Sara Arab ,  Dirk Block ,  Andrew Emili ,  Anthony Gramolini ,  Georg Hess ,  Hendrik Huedig ,  Peter Liu ,  David MacLennan

    IPC分类号： G01N33/53

    CPC分类号： G01N33/6893 ,  G01N2333/4722 ,  G01N2800/325

    摘要： The invention relates to a method for assessing heart failure in vitro and involves the steps of measuring in a sample the concentration of the marker biglycan, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for biglycan and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of biglycan as a marker protein in the assessment of heart failure, a marker combination comprising biglycan and a kit for measuring biglycan.

    摘要翻译： 本发明涉及一种用于评估体外心脏衰竭的方法，包括以下步骤：在样品中测量标记物双糖链球蛋白的浓度，任选地在样品中测量一种或多种其它心力衰竭标志物的浓度，以及 通过比较确定的双糖甘肽聚糖浓度和任选的一种或多种其他标记物测定的浓度与该参考群体中确定的该标记物或这些标记物的浓度进行比较来评估心力衰竭。 还公开了使用双糖链蛋白作为评估心力衰竭的标记蛋白，包括双糖链蛋白聚糖和用于测量双糖链球蛋白的试剂盒的标记组合。

    ENDOSTATIN AS A MARKER OF HEART FAILURE
    4.
    发明申请
    ENDOSTATIN AS A MARKER OF HEART FAILURE 审中-公开
    内分泌作为心脏失败的标记

    公开(公告)号：US20120009610A1

    公开(公告)日：2012-01-12

    申请号：US13228552

    申请日：2011-09-09

    申请人： Ursula-Henrike Wienhues-Thelen ,  Dirk Block ,  Hendrik Huedig

    发明人： Ursula-Henrike Wienhues-Thelen ,  Dirk Block ,  Hendrik Huedig

    IPC分类号： G01N33/566 ,  C12Q1/02

    CPC分类号： G01N33/6887 ,  G01N2333/515 ,  G01N2333/58 ,  G01N2333/78 ,  G01N2800/325

    摘要： Disclosed is a method for assessing heart failure in an individual including the steps of a) measuring in a sample obtained from the individual the concentration of the marker endostatin, of b) optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in step (a) and optionally the concentration(s) determined in step (b) to the concentration of this marker or these markers as established in a control sample. Also disclosed are the use of endostatin as a marker protein in the assessment of heart failure, a marker combination comprising endostatin, and a kit for measuring endostatin.

    摘要翻译： 公开了一种用于评估个体心脏衰竭的方法，包括以下步骤：a）在从个体获得的样品中测量标记物内皮抑制素的浓度，b）任选地在样品中测量一种或多种其他标记物 ），并且通过将步骤（a）中测定的浓度与步骤（b）中确定的浓度（可选地）与本对照样品中确定的该标志物或这些标记物的浓度进行比较来评价心力衰竭。 还公开了在评估心力衰竭中使用内皮抑制素作为标记蛋白，包含内皮抑素的标记物组合和用于测量内皮抑素的试剂盒。

    USE OF MIMECAN IN THE ASSESSMENT OF HEART FAILURE
    7.
    发明申请
    USE OF MIMECAN IN THE ASSESSMENT OF HEART FAILURE 审中-公开
    MIMECAN在心脏衰竭评估中的应用

    公开(公告)号：US20120156703A1

    公开(公告)日：2012-06-21

    申请号：US13359276

    申请日：2012-01-26

    申请人： Dirk Block ,  Sara Arab ,  Georg Hess ,  Hendrik Huedig ,  Peter Liu ,  Ursula-Henrike Wienhues-Thelen

    发明人： Dirk Block ,  Sara Arab ,  Georg Hess ,  Hendrik Huedig ,  Peter Liu ,  Ursula-Henrike Wienhues-Thelen

    IPC分类号： G01N33/566

    CPC分类号： G01N33/6893 ,  G01N33/6812 ,  G01N2333/4703 ,  G01N2800/325

    摘要： The disclosure relates to assessing heart failure in vitro by measuring the concentration of the marker mimecan in a sample, and optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration of mimecan and the one or more other marker(s) to reference concentrations of this (or these) marker(s) as established in a reference population. The one or more markers may be selected from the group comprising a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation. Also disclosed are the use of mimecan as a marker protein in the assessment of heart failure, a marker combination comprising mimecan, and a kit for measuring mimecan.

    摘要翻译： 本公开涉及通过测量样品中标记拟米卡因的浓度来评估体外心力衰竭，并且可选地在样品中测量一种或多种其他心力衰竭标志物的浓度，并通过比较心脏衰竭来评估心力衰竭 在参考群体中建立的，将拟米卡宁和一种或多种其它标记物浓度提高至（或这些）标记的参考浓度。 一种或多种标志物可以选自利尿钠肽标记物，心肌肌钙蛋白标记物和炎症标志物。 还公开了在评估心力衰竭中使用mimecan作为标记蛋白，包括mimecan的标记组合和用于测量mimecan的试剂盒。